Oruka Therapeutics (ORKA): General Counsel sold ~$30K
Paul T Quinlan, General Counsel at Oruka Therapeutics, sold ~$30K of Oruka Therapeutics shares.
- ~$30K
- Approx. value · 400 sh @ $74.90
- 39K
- Holds after · shares reported
- Traded
- Oct 20, 2026
- Filed
- Oct 21, 2026
What stands out in this filing
- The sale was 1.0% of the shares this insider held before it; the filing reports 38,595 shares afterwards.
- 400 shares at an average of $74.90 each, as reported on the form.
- Footnote references a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026.”
- Oct 1, 2026Insider · 1 personInsiders: 3 sales (~$2.1M)
- Oct 12, 2026Insider · 1 personInsiders: 4 sales (~$806K)
- Oct 15, 2026Insider · 1 personInsiders: 5 sales (~$524K)
- Oct 20, 2026 · this disclosureInsiderOfficer sold ~$30K of ORKA shares in the open market
What came next
- Oct 20, 2026Insider · 1 personInsiders: 4 sales (~$677K)
- Nov 2, 2026Insider · 1 personInsiders: 5 sales (~$2.4M)
- Nov 12, 2026Insider · 2 peopleInsiders: 12 sales (~$2.9M)
- Nov 16, 20265% stakeRTW Investments, LP reported a passive stake (13G) of 4.7%
- Nov 16, 20265% stakeT. Rowe Price Investment Management, Inc. reported a passive stake (13G) of 6.6%
- Nov 16, 2026Insider · 1 personInsiders: 6 sales (~$707K)
- Nov 20, 2026Insider · 1 personInsiders: 4 sales (~$854K)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Oruka Therapeutics
For Oruka Therapeutics, OQRO holds 45 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ORKA page.
Other recent filings by Paul T Quinlan, General Counsel
- SEC Form 4 at Oruka Therapeutics (ORKA)Nov 20, 2026
- SEC Form 4 at Oruka Therapeutics (ORKA)Nov 20, 2026
- SEC Form 4 at Oruka Therapeutics (ORKA)Nov 20, 2026
- SEC Form 4 at Oruka Therapeutics (ORKA)Nov 20, 2026
- SEC Form 4 at Oruka Therapeutics (ORKA)Oct 21, 2026
The full history of Paul T Quinlan, General Counsel is on the profile page.
How this filing works
Explore the data
Common questions
Which Oruka Therapeutics (ORKA) insider traded, and how much?
Paul T Quinlan, General Counsel at Oruka Therapeutics, sold ~$30K of Oruka Therapeutics shares. 400 shares at $74.90.
When did it happen, and when was it made public?
Traded: Oct 20, 2026. Filed: Oct 21, 2026. That is 1 day between the two dates.
What stands out in this filing?
The sale was 1.0% of the shares this insider held before it; the filing reports 38,595 shares afterwards. 400 shares at an average of $74.90 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Oruka Therapeutics recently?
For Oruka Therapeutics, OQRO holds 45 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ORKA page.
Does this mean ORKA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Oruka Therapeutics
- SEC Form 13F-HRNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Form 4Nov 16, 2026
- SEC Form 4Nov 16, 2026
- SEC Form 4Nov 16, 2026
Everything OQRO holds on this company is on its ORKA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data